In recent years, researchers have used the CRISPR/Cas9 system, adeno-associated viruses and other efficient gene editing tools to construct a large number of SLC knockout/knockdown or SLC-overexpressing animal models for screening disease risk sites and drug targets, which has greatly promoted the use of SLC transporters as therapeutic targets for metabolic diseases. The gene discussed is CCL21; the disease is metabolic disease.